Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:alsoKnownAs |
gptkb:Cobicistat
|
| gptkbp:approvedBy |
HIV/AIDS treatment
|
| gptkbp:ATCCode |
J05AG14
|
| gptkbp:CASNumber |
1004316-88-4
|
| gptkbp:combines |
gptkb:elvitegravir
emtricitabine tenofovir |
| gptkbp:developedBy |
gptkb:Gilead_Sciences
|
| gptkbp:hasMolecularFormula |
C40H53N7O5S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
GS-9350
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
Tybost
|
| gptkbp:mechanismOfAction |
CYP3A inhibitor
|
| gptkbp:notUsedAs |
antiviral drug
|
| gptkbp:sideEffect |
nausea
jaundice rash increased serum creatinine |
| gptkbp:usedAs |
pharmacokinetic enhancer
|
| gptkbp:bfsParent |
gptkb:DB06151
gptkb:DB04876 |
| gptkbp:bfsLayer |
7
|